Specifically, the anti-PD-1 and anti-PD-L1 therapy sensitized and prolonged the efficiency of the anti-angiogenic therapy, while the anti-angiogenic agents improved the treatment by promoting the endothelial venule formation and vessel normalization to enhance the infiltration of cytotoxic T cells for tumor destruction [141,143]. This evidence concerns the gene PDCD1 and neoplasm.